Cargando…
PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN-LABEL, MULTICENTER PHASE 1/2 TRIAL
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430145/ http://dx.doi.org/10.1097/01.HS9.0000974536.21928.ec |
| _version_ | 1785090885714706432 |
|---|---|
| author | Yang, Shenmiao Huang, Haiwen Zhou, Keshu Zhao, Xielan Han#, Yan-Qiu LI, Lindong Butturini, Anna Wang, Yiqiu Liu, Xiaofeng Lai, Peiqiong LI, Jianyong |
| author_facet | Yang, Shenmiao Huang, Haiwen Zhou, Keshu Zhao, Xielan Han#, Yan-Qiu LI, Lindong Butturini, Anna Wang, Yiqiu Liu, Xiaofeng Lai, Peiqiong LI, Jianyong |
| author_sort | Yang, Shenmiao |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430145 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104301452023-08-17 PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN-LABEL, MULTICENTER PHASE 1/2 TRIAL Yang, Shenmiao Huang, Haiwen Zhou, Keshu Zhao, Xielan Han#, Yan-Qiu LI, Lindong Butturini, Anna Wang, Yiqiu Liu, Xiaofeng Lai, Peiqiong LI, Jianyong Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430145/ http://dx.doi.org/10.1097/01.HS9.0000974536.21928.ec Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Yang, Shenmiao Huang, Haiwen Zhou, Keshu Zhao, Xielan Han#, Yan-Qiu LI, Lindong Butturini, Anna Wang, Yiqiu Liu, Xiaofeng Lai, Peiqiong LI, Jianyong PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN-LABEL, MULTICENTER PHASE 1/2 TRIAL |
| title | PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN-LABEL, MULTICENTER PHASE 1/2 TRIAL |
| title_full | PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN-LABEL, MULTICENTER PHASE 1/2 TRIAL |
| title_fullStr | PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN-LABEL, MULTICENTER PHASE 1/2 TRIAL |
| title_full_unstemmed | PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN-LABEL, MULTICENTER PHASE 1/2 TRIAL |
| title_short | PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: AN OPEN-LABEL, MULTICENTER PHASE 1/2 TRIAL |
| title_sort | pb1929: efficacy and safety of acalabrutinib in chinese patients with relapsed/refractory chronic lymphocytic leukemia: an open-label, multicenter phase 1/2 trial |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430145/ http://dx.doi.org/10.1097/01.HS9.0000974536.21928.ec |
| work_keys_str_mv | AT yangshenmiao pb1929efficacyandsafetyofacalabrutinibinchinesepatientswithrelapsedrefractorychroniclymphocyticleukemiaanopenlabelmulticenterphase12trial AT huanghaiwen pb1929efficacyandsafetyofacalabrutinibinchinesepatientswithrelapsedrefractorychroniclymphocyticleukemiaanopenlabelmulticenterphase12trial AT zhoukeshu pb1929efficacyandsafetyofacalabrutinibinchinesepatientswithrelapsedrefractorychroniclymphocyticleukemiaanopenlabelmulticenterphase12trial AT zhaoxielan pb1929efficacyandsafetyofacalabrutinibinchinesepatientswithrelapsedrefractorychroniclymphocyticleukemiaanopenlabelmulticenterphase12trial AT hanyanqiu pb1929efficacyandsafetyofacalabrutinibinchinesepatientswithrelapsedrefractorychroniclymphocyticleukemiaanopenlabelmulticenterphase12trial AT lilindong pb1929efficacyandsafetyofacalabrutinibinchinesepatientswithrelapsedrefractorychroniclymphocyticleukemiaanopenlabelmulticenterphase12trial AT butturinianna pb1929efficacyandsafetyofacalabrutinibinchinesepatientswithrelapsedrefractorychroniclymphocyticleukemiaanopenlabelmulticenterphase12trial AT wangyiqiu pb1929efficacyandsafetyofacalabrutinibinchinesepatientswithrelapsedrefractorychroniclymphocyticleukemiaanopenlabelmulticenterphase12trial AT liuxiaofeng pb1929efficacyandsafetyofacalabrutinibinchinesepatientswithrelapsedrefractorychroniclymphocyticleukemiaanopenlabelmulticenterphase12trial AT laipeiqiong pb1929efficacyandsafetyofacalabrutinibinchinesepatientswithrelapsedrefractorychroniclymphocyticleukemiaanopenlabelmulticenterphase12trial AT lijianyong pb1929efficacyandsafetyofacalabrutinibinchinesepatientswithrelapsedrefractorychroniclymphocyticleukemiaanopenlabelmulticenterphase12trial |